There were a lot of numbers thrown around at the House Committee for Oversight and Government Reform July 24 hearing on Medicare Part D.
There was $3.7 billion. That was the two-year "windfall" in sales to pharma for the top 100 dual-eligible drugs under...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?